TAI'AN, China, Sept. 9 /PRNewswire-Asia/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. ("Taibang") and Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today announced that the Company has appointed Dr. Vincent Yi-Wu Xie to be the Company's Director of Research and Development, effective September 1, 2009, to oversee the development of new biologic products covering processes, analytical methods and indications.
Dr. Xie is a veteran in the biopharmaceutical industry and has published several papers and articles related to the field of plasma-based research. He holds a number of patents related to his biopharmaceutical research, including research on plasma-derived hyperimmune globulins and alpha-1 proteinase inhibitor, and has received the Guangzhou City Science and Technology Award in connection with his work "Preparation of Equine Antibodies against Avian Influenza." Prior to joining China Biologic, Dr. Xie served from 2007 to 2009 as the General Manager of Research and Development at New a-IKOR Limited, a Hong Kong-based biopharmaceutical company, and from 2002 to 2007, as the Director of Research & Development at Advantek Serum Laboratories Limited, a Hong Kong plasma-based biopharmaceutical company. Dr. Xie has also conducted postdoctoral research in various departments in the University of Hong Kong and the Chinese University of Hong Kong.
"We are very pleased to have Dr. Xie join our research team," commented Mr. Chao Ming Zhao, CEO of China Biologic Products. "He brings years of research experience and managerial expertise related to the biopharmaceutical industry to China Biologic Products. We expect that his presence on our team will serve to strengthen our research and development efforts as part of our strategy to bring new higher margin products to market."
About China Biologic Products, Inc.
China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. It sells its products to hospitals and other healthcare facilities in China.
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the impact of the appointment of Mr. Xie as the Company's new Director of Research; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries, including the possibility that Mr. Xie's presence will advance the Company's strategy to bring new higher margin products to market; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
For more information, please contact:
Company Contact:
China Biologic Products, Inc.
Mr. Y. Tristan Kuo
Chief Financial Officer
Tel: +86-538-6202206
Email: IR@chinabiologic.com
Web: http://www.chinabiologic.com
Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (NY office)
Email: crocker.coulson@ccgir.com
Mr. Gary Chin
Tel: +1-646-213-1909
Web: http://www.ccgirasia.com
